Continued Progress at Cooper
We're increasing our fair value estimate on the narrow-moat company to reflect higher margin assumptions.
Narrow-moat Cooper Companies posted solid-second quarter earnings that were slightly ahead of our expectations, and we plan to increase our fair value estimate to reflect higher margin assumptions and management’s increased year-end outlook. Revenue increased 8% year over year to $552.4 million, with CooperVision up 4%, which fueled higher gross and operating margins stemming from improved manufacturing efficiencies and sales of the high-margin Biofinity products. We believe CooperVision’s diverse portfolio of daily and silicone hydrogel lenses contributed to Cooper’s growth across all geographic regions.
This quarter’s results suggest early contributions from CooperVision’s salesforce expansion. Cooper expanded its salesforce 16% year over year, which we believe directly translated to CooperVision’s 8% growth in the Americas, outpacing market growth of only 2%. We trust that this expanded salesforce will help CooperVision increasingly penetrate the Asia-Pacific and EMEA regions.
On a slightly negative note, we believe CooperVision will begin to contend with multiple issues in the long run. Cooper has benefited from growth in gross and operating margins due to operational efficiencies and new product lines, but we believe it will be increasingly difficult for its margin expansion story to persist, especially given the continuation of currency headwinds. Furthermore, Cooper has benefited from the stumbles at rival Bausch & Lomb and Alcon--something we do not expect to persist in the long run.
This quarter, CooperSurgical increased 23.9% year over year to $113.9 million, with strength coming from 52% constant-currency growth in the fertility division. We believe that as CooperSurgical integrates its numerous acquisitions, we will continue to see the segment outpace CooperVision in terms of revenue growth and encompass a greater proportion of Cooper’s total revenue.
Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.
Michael Waterhouse does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.